Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers.
To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin were determined, and area-under-the-curve values were calculated. None of the endocrinological parameters revealed any statistically significant changes. A trend could be found for an increased cortisol production under paroxetine (P = 0.069). ACTH, LH, and melatonin showed slight and non-significant decreases. Prolactin release was only marginally elevated (+7%). The mean sleep onset GH release (as measured for a time period of 180 min after sleep onset) was decreased by about 30% under paroxetine. However, statistical significance could not be reached. For hGH, there was a delayed mean GH-peak under paroxetine. Nocturnal testosterone secretion remained almost unaltered. The lack of significant endocrinological alterations might be partially explained by both adaptational phenomena under subchronic treatment conditions and the extended time span between the single morning dose and the registration period, respectively.
Schlösser
R
R
Department of Psychiatry, University of Mainz, Untere Zahlbacher Str. 8, D-55131, Mainz, Germany. schloess@mail.uni-mainz.de
Wetzel
H
H
Dörr
H
H
Rossbach
W
W
Hiemke
C
C
Benkert
O
O
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D002940:Circadian Rhythm; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004569:Electroencephalography; D006728:Hormones / Q000097:blood*; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008550:Melatonin / Q000097:blood; D017374:Paroxetine / Q000008:administration & dosage*; D010919:Placebos; D011388:Prolactin / Q000097:blood; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*
D000324:Adrenocorticotropic Hormone; D006728:Hormones; D019382:Human Growth Hormone; D006854:Hydrocortisone; D007986:Luteinizing Hormone; D008550:Melatonin; D017374:Paroxetine; D010919:Placebos; D011388:Prolactin; D017367:Selective Serotonin Reuptake Inhibitors